Access the full text.
Sign up today, get DeepDyve free for 14 days.
Fernanda ao-Flores, M. Emmons, Michael Durante, F. Kinose, Biswarup Saha, B. Fang, J. Koomen, S. Chellappan, S. Maria-Engler, U. Rix, J. Licht, J. Harbour, K. Smalley (2019)
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal MelanomaClinical Cancer Research, 25
Hanyin Cheng, M. Terai, Ken Kageyama, S. Ozaki, P. Mccue, Takami Sato, A. Aplin (2015)
Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.Cancer research, 75 13
F. Faião-Flores, D. Alves-Fernandes, P. Pennacchi, S. Sandri, A. Vicente, C. Scapulatempo-Neto, V. Vazquez, R. Reis, J. Chauhan, C. Goding, K. Smalley, S. Maria-Engler (2016)
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cellsOncogene, 36
Sreenath Sharma, Diana Lee, Bihua Li, M. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. Fischbach, Kwok-kin Wong, K. Brandstetter, Ben Wittner, Sridhar Ramaswamy, M. Classon, J. Settleman (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 141
C. Stresemann, F. Lyko (2008)
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 123
K. Smalley, Mercedes Lioni, K. Noma, N. Haass, M. Herlyn (2008)
In vitro three-dimensional tumor microenvironment models for anticancer drug discoveryExpert Opinion on Drug Discovery, 3
Hanyin Cheng, Vivian Chua, Connie Liao, Timothy Purwin, M. Terai, Ken Kageyama, M. Davies, Takami Sato, A. Aplin (2017)
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal MelanomaMolecular Cancer Therapeutics, 16
G. Ambrosini, C. Pratilas, L. Qin, M. Tadi, O. Surriga, R. Carvajal, G. Schwartz (2012)
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK ResistanceClinical Cancer Research, 18
C. Raamsdonk, V. Bezrookove, G. Green, J. Bauer, Lona Gaugler, J. O'Brien, E. Simpson, G. Barsh, Boris Bastian (2008)
Frequent somatic mutations of GNAQ in uveal melanoma and blue neviNature, 457
(2020)
Additional supporting information may be found online in the Supporting Information section
R. Carvajal, S. Piperno-Neumann, E. Kapiteijn, P. Chapman, S. Frank, A. Joshua, J. Piulats, P. Wolter, V. Cocquyt, B. Chmielowski, T. Evans, L. Gastaud, G. Linette, C. Berking, J. Schachter, M. Rodrigues, A. Shoushtari, Delyth Clemett, D. Ghiorghiu, G. Mariani, Shirley Spratt, Susan Lovick, P. Barker, E. Kilgour, Z. Lai, G. Schwartz, P. Nathan (2018)
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 12
M. Lübbert, S. Suciu, L. Baila, B. H. Rüter, U. Platzbecker, A. Giagounidis, P. W. Wijermans (2011)
Low‐dose decitabine versus best supportive care in elderly patients with intermediate‐ or high‐risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group, 29
Fa-Xing Yu, Jing Luo, Jung-Soon Mo, Guangbo Liu, Young Kim, Z. Meng, Ling Zhao, Gholam Peyman, H. Ouyang, Wei Jiang, Jiagang Zhao, Xu Chen, Liangfang Zhang, Cun-Yu Wang, B. Bastian, Kang Zhang, K. Guan (2014)
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.Cancer cell, 25 6
Y. Shao, A. Aplin (2012)
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanomaCell Death and Differentiation, 19
K. Smalley, R. Contractor, Thiennga Nguyen, M. Xiao, R. Edwards, Viswanathan Muthusamy, A. King, K. Flaherty, M. Bosenberg, M. Herlyn, K. Nathanson (2008)
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.Cancer research, 68 14
G. Ambrosini, R. Khanin, R. Carvajal, G. Schwartz (2014)
Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma CellsMolecular Cancer Therapeutics, 13
J. Harbour (2012)
Update in uveal melanoma.Clinical advances in hematology & oncology : H&O, 10 7
K. Smalley, N. Haass, P. Brafford, Mercedes Lioni, K. Flaherty, M. Herlyn (2006)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesMolecular Cancer Therapeutics, 5
Karin Schmelz, N. Sattler, Mandy Wagner, M. Lübbert, B. Dörken, I. Tamm (2005)
Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanismsLeukemia, 19
M. Emmons, F. Faião-Flores, Ritin Sharma, R. Thapa, J. Messina, J. Becker, D. Schadendorf, E. Seto, V. Sondak, J. Koomen, Y. Chen, E. Lau, L. Wan, J. Licht, K. Smalley (2019)
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.Cancer research, 79 11
K. Maes, E. Smedt, M. Lemaire, H. Raeve, E. Menu, E. Valckenborgh, S. Mcclue, K. Vanderkerken, E. Bruyne (2014)
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myelomaOncotarget, 5
Xu Chen, Qiuxia Wu, P. Depeille, Peirong Chen, S. Thornton, H. Kalirai, S. Coupland, J. Roose, B. Bastian (2017)
RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.Cancer cell, 31 5
R. Carvajal, J. Sosman, J. Quevedo, M. Milhem, A. Joshua, R. Kudchadkar, G. Linette, T. Gajewski, J. Lutzky, D. Lawson, C. Lao, P. Flynn, M. Albertini, Takami Sato, K. Lewis, A. Doyle, K. Ancell, K. Panageas, M. Bluth, C. Hedvat, J. Erinjeri, G. Ambrosini, B. Marr, D. Abramson, M. Dickson, J. Wolchok, P. Chapman, G. Schwartz (2014)
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.JAMA, 311 23
Harbour Jw (2012)
Update in uveal melanoma.Clinical advances in hematology & oncology, 10
Partha Das, R. Singal (2004)
DNA methylation and cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 22
MEK inhibitors (MEKi) demonstrate anti‐proliferative activity in patients with metastatic uveal melanoma, but responses are short‐lived. In the present study, we evaluated the MEKi trametinib alone and in combination with drugs targeting epigenetic regulators, including DOT1L, EZH2, LSD1, DNA methyltransferases, and histone acetyltransferases. The DNA methyltransferase inhibitor (DNMTi) decitabine effectively enhanced the anti‐proliferative activity of trametinib in cell viability, colony formation, and 3D organoid assays. RNA‐Seq analysis showed the MEKi‐DNMTi combination primarily affected the expression of genes involved in G1 and G2/2M checkpoints, cell survival, chromosome segregation and mitotic spindle. The DNMTi‐MEKi combination did not appear to induce a DNA damage response (as measured by γH2AX foci) or senescence (as measured by β‐galactosidase staining) compared to either MEKi or DNMTi alone. Instead, the combination increased expression of the CDK inhibitor p21 and the pro‐apoptotic protein BIM. In vivo, the DNMTi‐MEKi combination was more effective at suppressing growth of MP41 uveal melanoma xenografts than either drug alone. Our studies indicate that DNMTi may enhance the activity of MEKi in uveal melanoma.
Pigment Cell & Melanoma Research – Wiley
Published: May 1, 2020
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.